Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
It has exercised an option on TriGrid, which was developed by Ichor Medical Systems
In an update, the speciality pharma company told investors it was acquiring the global rights to Proleukin for an undisclosed sum from Novartis
The US Food & Drug Administration has given the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours
The cell therapy specialist also reported there had been industry interest around its main programmes
The gynaecological disorder occurs when tissue similar to the lining of the uterus, or endometrium, migrates outside of the womb, generally to the fallopian tubes, ovaries and tissue around the uterus
The company said it will use Veritas’ cannabis strain lead selection to assist its application to the Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing licence
In an update on trading, chief executive David Budd said he was pleased with the progress
The drug developer has drafted in a new director as well as recruiting a head of clinical development
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.